Inhibikase Therapeutics, Inc. IKT R2KPHARMA
Company Overview
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +46.20% |
| 6 Months: | +32.98% |
| 3 Months: | +53.37% |
| 1 Month: | +3.73% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.77 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IKT Inhibikase Therapeutics, Inc. R2KPHARMA | 2.50 | -5.68 | $392.58M | 0.00% | -30.85% | -40.23% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 270.79K | 219.59K | 37.68K | 1.41M | 1.36M | 328.46K | 46.03K | 6.55K | 7.29K | 64.52K | 116.41K | 79.57K | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.76M | 11.19M | 13.26M | 13.13M | 18.22M |
| Operating Income | -540.01K | -413.92K | -663.71K | -2.63M | -2.63M | -4.47M | -4.64M | -4.64M | -4.51M | -4.71M | -6.20M | -4.77M | -4.78M | -5.05M | - | - | -15.76M | -11.19M | -13.26M | -13.13M | -18.22M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.75M | -11.17M | -13.24M | -13.13M | -18.22M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.68M | -9.92M | -11.93M | -12.73M | -16.38M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -547.44K | -421.87K | -670.60K | -2.64M | -2.64M | -4.47M | -4.64M | -4.64M | -4.49M | -4.48M | -5.78M | -4.60M | -4.65M | -4.96M | - | - | -13.68M | -9.92M | -11.93M | -12.73M | -16.38M |
| Diluted EPS | - | - | - | - | -0.22 | -0.18 | -0.18 | -1.10 | -1.06 | -0.98 | -1.11 | -0.86 | -0.73 | -0.66 | -0.65 | - | -0.15 | -0.11 | -0.13 | - | -0.10 |
| R&D Expense | 283.11K | 263.18K | 120.57K | 2.43M | 2.38M | 3.15M | 3.02M | 2.98M | 2.98M | 2.85M | 4.54M | 3.23M | 2.75M | 3.08M | 4.19M | - | 10.51M | 5.27M | 7.65M | - | 10.84M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 698.47K | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 18.13M | 20.09M | 28.59M | 53.35M |
| Operating Income | -2.82M | - | -18.13M | -20.09M | -28.59M | -53.35M |
| EBITDA | - | - | -18.12M | -19.91M | -28.56M | -53.29M |
| Interest Expense | - | 19.92K | - | - | - | - |
| Pretax Income | - | - | -18.05M | -19.03M | -27.52M | -48.26M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -2.85M | - | -18.05M | -19.03M | -27.52M | -48.26M |
| Diluted EPS | - | - | -4.28 | -3.16 | -1.16 | -0.49 |
| R&D Expense | 893.80K | 11.36M | 12.03M | 13.62M | 17.21M | 29.79M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 14.78M | 42.47M | 24.94M | 14.51M | 98.60M | 181.20M |
| Total Equity | -4.49M | 9.78M | 38.42M | 21.04M | 10.98M | 94.87M | 172.90M |
| Cash & Equivalents | - | - | 40.75M | 7.19M | 9.20M | 97.50M | 178.80M |
| Long Term Debt | - | - | 248.91K | - | 381.78K | - | - |
| Total Liabilities | - | 5.00M | 4.05M | 3.90M | 3.53M | 3.73M | 8.30M |
| Current Liabilities | - | 4.72M | 4.05M | 3.70M | 3.44M | 3.73M | 8.30M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.13M | -14.30M | -17.35M | -18.09M | -19.15M | -27.79M |
| Investing Cash Flow | - | 0 | -16.01M | 11.66M | -37.00M | 2.05M |
| Financing Cash Flow | 15.06M | 41.09M | -204.77K | 8.41M | 103.48M | 108.46M |
| Capital Expenditure | - | -0 | -243.25K | -14.24K | -0 | -13.40K |
| Free Cash Flow | - | -14.30M | -17.59M | -18.10M | -19.15M | -27.80M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -403.5% | - | - | - | - | - |
| Net Margin % | -407.7% | - | - | - | - | - |
| ROE % | -29.1% | - | -85.8% | -173.3% | -29.0% | -27.9% |
| ROCE % | -28.0% | - | -85.3% | -181.5% | -30.1% | -30.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Sands Capital Alternatives, LLC | 9.33% | 13.02M | $31.38M |
| 2 | Soleus Capital Management, L.P. | 7.79% | 10.88M | $26.21M |
| 3 | Trails Edge Capital Partners, LP | 6.49% | 9.05M | $21.81M |
| 4 | Fairmount Funds Management LLC | 6.18% | 8.62M | $20.79M |
| 5 | Blackrock Inc. | 5.57% | 7.77M | $18.72M |
| 6 | Adar1 Capital Management, LLC | 5.29% | 7.39M | $17.80M |
| 7 | Blackstone Inc | 4.26% | 5.94M | $14.31M |
| 8 | Siren, L.L.C. | 4.19% | 5.85M | $14.10M |
| 9 | Commodore Capital Lp | 3.87% | 5.40M | $13.01M |
| 10 | Vanguard Capital Management LLC | 3.54% | 4.94M | $11.89M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IKT
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Average Recommendation of "Buy" from Brokerages - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxNZVJNNlI2V2k2T05PVmJpMVhqek54RTI1Vk40ZTNMTmdELV8xb0NfSlJ0QzBZYy1jYjg0UHVoSFVuSTRMZF9HR3dJcWQzX2V0ZG1SWDdQYndSNDZHX19JN2lNaEZzWjR4ZWNIMUJ5OVBia1E3eVpobE9KQWdSSWM5djVyX0VPUWpJSmJlRm…
Biotech Stocks At 52-Week Highs - ATTO, HALO, IKT, TVTX, ATRC - RTTNews
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPMkxGWkhGc2Q2VGoyXzl2Y2o0VHB1dlBlV1EtbFVfb2lITnBEcU1OMEJFUF9hNERsOU1yN1BkS29YYi1Ic0lRa2RSZ0ozV1lrcU1OdkVWRVZfTTl1c0FiRzFXZTNRUWlaaG9LZ2lIcWNFbkpzWmVRcmpyTlJoVURPMVVxRjBUQ19QSV90N1…
Inhibikase's IKT-001 gets FDA orphan designation for PAH, about 50,000 Americans - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPZVFUaHdobHNMRF82MGVOOHRmMVQtQlEwSFowM1ByLV8wZHgzY1lPcHVWV3EweFpYcGdneW1tX1hlMzRwdlFYTHFBclNIVkNma3dSckFGOHR3MDJqenB5ZW14UDFKSDdJdkFzakZXTEs3Nkxkc1FhamxvUUttYXdZTEZId1lsY2lTbTZXWk…
IKT Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5iS051Z0xjdkFCdElEdUJId3R2OHpRVmdkRzV4NzZxX3BnRHgwNzNrdEkycTdZRWsxVW1ZT0NJazdJVTNfRVBTMmxzUlVEMlB4b2pHZjJsaVZyU0VzQzlMQmpRS3JDZEwzclBYZTZuVnJOWnR3UjJMeQ?oc=5" target="_blank">IKT F…
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxQemtiOTFFNDJGZDlVU3FKRHdjZXpQd0VZTm5DU3V1d25ubGF3anNhUU1XUGhnM2M2emVOb0ZTQk1ncHN1MUNhNVFXdDl3Qlh2cHFpS2NxRkNPMlZRcjJQT0t5VjRiU3JJTXZTTWFSd2pTeUNRbUlaa0pRSE9UUkZmYmJ3?oc=5" target=…
A Look At Inhibikase Therapeutics (IKT) Valuation After New FDA Designations And Phase 2a Trial Progress - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPNllBcnFOald0VDN3dDlVOWNPdHRVZkttME5GVHdiSUl3TWVEYnFPM0dWSGtCVEVGc3RnTXhRcFBEN19vX3B5bjFycjk4MTNKYzdnVWVsdVhrNlVYRXpCTVp6RXVIb3VWZEtYOEpkaERpWEwtYnpKbnhnZ21Zdl9hcy02bG8tdHdWWk1CRV…
IKT — Frequently Asked Questions
What is the current share price of Inhibikase Therapeutics, Inc. (IKT)?
As of 2026-09-07 16:24 PDT, Inhibikase Therapeutics, Inc. (IKT) trades at $2.50 on NasdaqCM. Its 52-week range is $1.41 to $2.52.
What is the market capitalisation of IKT?
Inhibikase Therapeutics, Inc. (IKT) has a market capitalisation of $392.58M on NasdaqCM.
What is the P/E ratio of IKT?
IKT trades at a trailing price-to-earnings (P/E) ratio of -5.68. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.51.
What is the return on equity (ROE) of IKT?
IKT has a return on equity (ROE) of -40.23%. Its return on capital employed (ROCE) is -30.85%.
Is IKT a good stock to buy?
This page provides a data-driven analysis of Inhibikase Therapeutics, Inc. (IKT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.